WO2001047529A2 - Association de deoxyfructosazine eit d'un antidiabetique agoniste du recepteur gamma-active par le proliferateur de peroxisome - Google Patents
Association de deoxyfructosazine eit d'un antidiabetique agoniste du recepteur gamma-active par le proliferateur de peroxisome Download PDFInfo
- Publication number
- WO2001047529A2 WO2001047529A2 PCT/FR2000/003606 FR0003606W WO0147529A2 WO 2001047529 A2 WO2001047529 A2 WO 2001047529A2 FR 0003606 W FR0003606 W FR 0003606W WO 0147529 A2 WO0147529 A2 WO 0147529A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- deoxyfructosazine
- association
- antidiabetic
- agonist
- troglitazone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Definitions
- the present invention relates to the combination of deoxyfructosazine and an antidiabetic agonist of the gamma receptor activated by the peroxisome proliferator (PPAR ⁇ ), the pharmaceutical compositions containing this association and their use in the prevention and / or treatment of type diabetes. 2 and its complications.
- PPAR ⁇ peroxisome proliferator
- deoxyfructosazine or (2 - [(R, 2S, 3R) (l, 2,3,4-tetrahydroxybutyl] -5- [2'S, 3'R) (2, 3 ', 4'-trihydroxybutylpyrazine)] is known for its anti-diabetic properties (WO97 / 28813).
- the antidiabetic agents that are agonists of the gamma receptor activated by the peroxisome proliferator (PPAR ⁇ ) are used in particular in the treatment of insulin-independent diabetes mellitus. They are generally used in addition to a diet.
- troglitazone EPI 39421, WO9727191, GB2335597
- rosiglitazone Avandia R
- pioglitazone Actos R , MCC555 (J. Biol. Chem., 1998, 273, 32679)
- GW1929 Diabetes, 1999, 48, 1415
- JTT501 Br. J. Pharmacol., 1998, 125, 1744
- the combination of anti-diabetic agonists of the gamma receptor activated by the peroxisome proliferator (PPAR ⁇ ) and deoxyfructosazine has a synergistic effect in the treatment of type 2 diabetes and its complications. More particularly, the invention relates to combinations of deoxyfructosazine and troglitazone, rosiglitazone, pioglitazone, MCC555, GW1929 or JTT501 or their pharmaceutically acceptable salts.
- the invention relates to combinations of deoxyfructosazine and troglitazone, rosiglitazone or pioglitazone or their pharmaceutically acceptable salts.
- the activity of the associations can be determined by the methods commonly used by those skilled in the art. Among these methods, the following methods can in particular be used:
- mice Male Wistar rats weighing 180 to 200 g are made diabetic by intravenous injection of 60 mg / kg of streptozotocin. After 72 hours, the blood sugar of the animals is measured on the glucometer. Animals with a blood sugar lower than 2 g / 1 are not selected for the study and those with a blood sugar higher than 2 g / 1 are treated, orally, by gavage using a gastric tube, as a single dose of either deoxyfructosazine alone (5-50-100-150 mg / kg) or troglitazone alone (50-100-200 mg / kg) or rosiglitazone alone (2-5 mg / kg) or pioglitazone alone (2-5-10 mg / kg) or a combination of deoxyfructosazine and troglitazone or deoxyfructosazine and rosiglitazone or deoxyfructosazine and pioglitazone. A group of animals receives only the vehicle. Blood sugar levels are
- Animals with a blood sugar lower than 2 g / 1 are not selected for the study, those with a blood sugar higher than 2 g / 1 are treated, orally, by gavage using a gastric tube, as a daily dose for 30 days either deoxyfructosazine alone (5-50-100-150 mg / kg) or troglitazone alone (50-100-200 mg / kg) or rosiglitazone alone (2-5 mg / kg) or pioglitazone alone (2-5-10 mg / kg) or a combination of deoxyfructosazine and troglitazone or deoxyfructosazine and rosiglitazone or deoxyfructosazine and pioglitazone.
- a group of animals receives only the vehicle. Blood sugar levels are measured once a day.
- tests A and B demonstrate that, in the animals receiving the association, the blood sugar levels are much lower than those of the control animals and those of the animals treated with a single antidiabetic.
- mice raised in Madagascar are given orally by gavage for 4 days either deoxyfructosazine alone (5-50-100-150 mg / kg) or troglitazone alone (50-100-200 mg / kg) or rosiglitazone alone (2-5 mg / kg) or pioglitazone alone (2- 5-10 mg / kg) or a combination of deoxyfructosazine and troglitazone or deoxyfructosazine and rosiglitazone or deoxyfructosazine and pioglitazone.
- 3 hours after the last treatment 2 g / kg of an aqueous glucose solution are given orally. Blood glucose levels are determined 20 minutes later using a glucometer. In this test, the results obtained demonstrate that, in the animals receiving the combination, the increase in the concentration of blood glucose is markedly reduced compared to that of the untreated animals and that of the animals treated with a single antidiabetic.
- Obese Zucker (fa / fa) rats aged 5-6 weeks are treated, orally, in a single gavage, for 7 and 14 days with deoxyfructosazine alone (5-50-100-150 mg / day / kg) or troglitazone alone (50-100-200 mg / kg) or rosiglitazone alone (2-5 mg / kg) or pioglitazone alone (2-5-10 mg / kg) or a combination of deoxyfructosazine and troglitazone or deoxyfructosazine and rosiglitazone or deoxyfructosazine and pioglitazone.
- the control groups are force-fed under the same conditions with the excipient alone.
- the food intake and the weight of the animals are measured every day during the experiment. After 7 and 14 days, the rats are anesthetized with pentobarbital. A glucose tolerance test (0.5 g / kg) is carried out intravenously and blood samples are taken at times 5, 10, 15, 20, 25 and 30 minutes after the injection in order to measure blood sugar and insulin levels.
- these associations are therefore useful in the prevention and / or treatment of type 2 diabetes.
- These associations can also be used in the complications of diabetes such as hyperlipemia, disorders of lipid metabolism, dyslipemia, obesity , diabetic cataracts, diabetic neuropathy in its various forms (peripheral polyneuropathies and its manifestations such as paraesthesia, hyperesthesia and pain, mononeuropathy, radiculopathy, autonomic neuropathy, diabetic muscular atrophy), manifestations of diabetic foot (ulcers of the lower extremities and foot), diabetic nephropathy in its diffuse and nodular forms.
- the combination can be used orally, parenterally or rectally either simultaneously or separately or over a period of time.
- the present invention also relates to pharmaceutical compositions comprising the combination of deoxyfructosazine and an antidiabetic agonist of the gamma receptor activated by the peroxisome proliferator (PPAR ⁇ ) preferably chosen from troglitazone, rosiglitazone, pioglitazone, GW1929 , JTT501 and their pharmaceutically acceptable salts and, more particularly troglitazone, rosiglitazone and pioglitazone and their pharmaceutically acceptable salts, in the pure state or in the form of a combination with one or more diluents and / or adjuvants compatible and pharmaceutically acceptable and / or optionally in combination with another pharmaceutically compatible and physiologically active product.
- the products that make up the association can be administered simultaneously, separately or in a spread over time so as to obtain the maximum effectiveness of the association.
- compositions for oral administration tablets, pills, powders (gelatin capsules, cachets) or granules can be used.
- the active ingredients are mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon.
- these compositions can also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
- compositions for oral administration use may be made of pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or oil paraffin.
- inert diluents such as water, ethanol, glycerol, vegetable oils or oil paraffin.
- These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
- the sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspensions or emulsions.
- solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other organic solvents can be used. suitable.
- These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
- compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene glycols.
- the present invention also relates to the method of prevention and / or treatment of type 2 diabetes and its complications which consists in administering to the patient a combination of deoxyfructosazine and an antidiabetic agonist of the gamma receptor activated by the peroxisome proliferator (PPAR ⁇ ) chosen, from preferably, among troglitazone, rosiglitazone, pioglitazone, GW1929, JTT501 and their pharmaceutically acceptable salts and, more particularly troglitazone, rosiglitazone and pioglitazone and their pharmaceutically acceptable salts, either simultaneously or separately or spread out in the time.
- PPAR ⁇ peroxisome proliferator
- the doses depend on the desired effect, the duration of the treatment and the route of administration used and the initial blood sugar level.
- the doses of the gamma receptor-activated agonist anti-diabetic by the peroxisome proliferator (PPAR ⁇ ) will be determined on a case-by-case basis. They will generally be identical to or lower than the doses recommended for single use. Thus, the dose will be 200 to 600 mg / day of troglitazone or 4 to 8 mg / day of rosiglitazone or 15 to 45 mg / day of pioglitazone.
- the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated such as blood sugar levels.
- the present invention also relates to the use of a combination of deoxyfructosazine and an antidiabetic agonist of the gamma receptor activated by the peroxisome proliferator (PPAR ⁇ ) preferably chosen from troglitazone, rosiglitazone, pioglitazone, GW1929 , JTT501 and their pharmaceutically acceptable salts and, more particularly troglitazone, rosiglitazone and pioglitazone and their pharmaceutically acceptable salts preparation of a medicament useful for the prevention and / or treatment of type 2 diabetes and its complications.
- PPAR ⁇ peroxisome proliferator
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU26879/01A AU2687901A (en) | 1999-12-23 | 2000-12-16 | Association of deoxyfructosazine and a peroxisome proliferating gamma-activated receptor agonist antidiabetic |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9916359A FR2802815A1 (fr) | 1999-12-23 | 1999-12-23 | Association de deoxyfructosazine et d'un antidiabetique agoniste du recepteur gamma-active par le proliferateur de peroxisome |
FR99/16359 | 1999-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001047529A2 true WO2001047529A2 (fr) | 2001-07-05 |
WO2001047529A3 WO2001047529A3 (fr) | 2002-10-24 |
Family
ID=9553731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/003606 WO2001047529A2 (fr) | 1999-12-23 | 2000-12-20 | Association de deoxyfructosazine eit d'un antidiabetique agoniste du recepteur gamma-active par le proliferateur de peroxisome |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2687901A (fr) |
FR (1) | FR2802815A1 (fr) |
WO (1) | WO2001047529A2 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2766183A1 (fr) * | 1997-07-17 | 1999-01-22 | Rhone Poulenc Rorer Sa | Medicaments contenant des polyhydroxybutylpyrazines, les polyhydroxybutylpyrazines nouvelles et leur preparation |
-
1999
- 1999-12-23 FR FR9916359A patent/FR2802815A1/fr active Pending
-
2000
- 2000-12-16 AU AU26879/01A patent/AU2687901A/en not_active Abandoned
- 2000-12-20 WO PCT/FR2000/003606 patent/WO2001047529A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2766183A1 (fr) * | 1997-07-17 | 1999-01-22 | Rhone Poulenc Rorer Sa | Medicaments contenant des polyhydroxybutylpyrazines, les polyhydroxybutylpyrazines nouvelles et leur preparation |
Non-Patent Citations (1)
Title |
---|
CHARBONNEL B.: "ÄCurrent management strategies in type 2 diabetesÜ. STRATEGIES ACTUELLES DE PRISE EN CHARGE DU DIABETE DE TYPE 2." DISEASE MANAGEMENT AND HEALTH OUTCOMES, (1998) 4/SUPPL. 1 (13-28)., XP000949819 * |
Also Published As
Publication number | Publication date |
---|---|
AU2687901A (en) | 2001-07-09 |
WO2001047529A3 (fr) | 2002-10-24 |
FR2802815A1 (fr) | 2001-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0678026B1 (fr) | Application de la carbamazepine et de l'oxcarbazepine dans le traitement de la maladie de parkinson et des syndromes parkinsoniens | |
CA2329636C (fr) | Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson | |
WO1994020103A1 (fr) | Application du riluzole dans le traitement du neuro-sida | |
WO2001047529A2 (fr) | Association de deoxyfructosazine eit d'un antidiabetique agoniste du recepteur gamma-active par le proliferateur de peroxisome | |
WO2001047527A1 (fr) | Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees | |
WO2001047522A2 (fr) | Association de deoxyfructosazine et d'un antidiabetique de la famille des biguanides | |
FR2619713A1 (fr) | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression | |
FR2802816A1 (fr) | Association de deoxyfructosazine et d'un antidiabetique inhibiteur d'alpha-glucosidase | |
EP1189617B1 (fr) | Association pharmaceutique a activite analgesique contenant du paracetamol et de la buspirone | |
CA2393523C (fr) | Association de cyamemazine et d'un neuroleptique atypique | |
CA2350671C (fr) | Association riluzole et alpha-tocopherol | |
FR2797399A1 (fr) | Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines | |
CA2319686C (fr) | Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet | |
CA2696918C (fr) | Compose pour son utilisation dans le traitement des neuropathies peripheriques | |
WO1998035670A1 (fr) | Produit contenant de l'idazoxan et de la 1-dopa comme preparation pharmaceutique combinee utilise pour la maladie de parkinson | |
FR2460671A1 (fr) | Nouvelles compositions pharmaceutiques a base d'un derive de l'indole et d'une benzodiazepine | |
EP1523321A1 (fr) | Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |